Indoco Remedies' Q2 FY 2025-26 Quarterly Results

Result Summary

• Indoco Remedies Ltd reported a 10.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.8%.
• Its expenses for the quarter were up by 4.7% QoQ and 13.5% YoY.
• The net profit decreased 74.7% QoQ and decreased 8.0% YoY.
• The earnings per share (EPS) of Indoco Remedies Ltd declined at 1 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Indoco Remedies Ltd is a prominent pharmaceutical company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company operates in both domestic and international markets, contributing significantly to the healthcare industry. Indoco Remedies has a diverse product portfolio that includes a wide range of therapeutic segments such as anti-infectives, anti-diabetics, anti-inflammatory, and respiratory. The company is known for its focus on research and development to enhance its product offerings and maintain a competitive edge. As of the latest information, there are no major new developments publicly available.

Revenue

In the second quarter of fiscal year 2026 (Q2FY26), Indoco Remedies Ltd reported a total income of ₹485.43 crores. This represents a quarter-over-quarter (QoQ) increase of 10.4% from ₹439.52 crores in Q1FY26. Year-over-year (YoY), the total income grew by 11.8% from ₹434.22 crores in Q2FY25. The growth in revenue reflects the company's ability to enhance its sales performance over both the preceding quarter and the same quarter in the previous year. This positive revenue trend demonstrates the company's operational capacity in expanding its market reach and possibly improving its product offerings.

Profitability

For Q2FY26, Indoco Remedies Ltd recorded a profit before tax (PBT) of -₹13.53 crores, which shows a significant improvement from a PBT of -₹36.66 crores in Q1FY26, translating to a QoQ change of -63.1%. However, compared to Q2FY25, where the PBT was -₹4.84 crores, this reflects a YoY change of 179.5%. The tax for the quarter was -₹4.32 crores, which saw an increase of 1293.5% QoQ from -₹0.31 crores and a YoY decrease of 183.6% from ₹5.17 crores. Consequently, the profit after tax (PAT) was reported at -₹9.21 crores, showing an improvement of 74.7% from -₹36.35 crores in Q1FY26 and a slight improvement of 8.0% from -₹10.01 crores in Q2FY25. The earnings per share (EPS) also improved QoQ by 74.6% to -₹1.00 from -₹3.94, and by 7.4% YoY from -₹1.08.

Operating Metrics

Total expenses for Q2FY26 stood at ₹498.43 crores, reflecting a QoQ increase of 4.7% from ₹476.18 crores in Q1FY26 and a YoY increase of 13.5% from ₹439.06 crores in Q2FY25. The expense growth rate is slightly lower than the income growth rate QoQ but higher YoY, indicating changes in cost structure or operational scaling. The company's operational efficiency can be examined through these expense trends, providing insights into cost management practices and potential areas for optimization. The observed financial metrics indicate a shift in the company's financial dynamics over the past quarters, with significant improvements in profit-related figures despite rising expenses.